A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

This study tests whether a combination of immune-calming drugs — a low dose of ATG (a medication that reduces immune attack) followed by either adalimumab or verapamil — can help preserve the remaining insulin-producing cells in young people newly diagnosed with type 1 diabetes. **You may be eligible if...** - You are between 9 and under 21 years old - You were diagnosed with type 1 diabetes within the last 6 months - You have at least one positive diabetes-related antibody in your blood - Your pancreas still produces some insulin (confirmed by a specific blood test) - You weigh more than 30 kg and have a BMI below the 95th percentile for your age - You are willing to follow intensive diabetes management during the study **You may NOT be eligible if...** - You were diagnosed more than 6 months ago - Your pancreas produces very little or no insulin - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.